Celcuity

Scientific Posters & Publications

Drug development backed by sound research

Below are a sample of innovative research published and presented by our team and our collaborators.

Filter by Cancer Type:

2021
Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer

Rachel M. Layman, Robert Wesolowski, Hyo Han, Jennifer M. Specht, Erica M. Stringer-Reasor, E. Claire Dees, Peter Kabos, Ingrid A. Mayer, Ulka Vaishampayan, Janice Lu, Keerthi Gogineni, Aditya Bardia, Anne F. Schott, Maysa M. Abu-Khalaf, Doug Hawkins, Brian Sullivan, Igor Gorbatchevsky, Hope S. Rugo

2021 San Antonio Breast Cancer Symposium (SABCS)
2021
Phase I dose-escalation study of the dual PI3K-mTORC1/2 inhibitor gedatolisib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res;27:5012–9, 2021

Ilaria Colombo, Sofia Genta, Federica Martorana, Monia Guidi, Milo Frattini, Eleftherios Pierre Samartzis, Simone Brandt, Sheila Gaggetta, Laura Moser, Mariarosa Pascale, Tatiana Terrot, Cristiana Sessa, and Anastasios Stathis

Clinical Cancer Research
2021
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer, Gynecologic Oncology 142, 62–69, 2016

Josep María del Campo, Michael Birrer, Craig Davis, Keiichi Fujiwara, Ashwin Gollerkeri, Martin Gore, Brett Houk, Susie Lau, Andres Poveda, Antonio González-Martín, Carolyn Muller, Kei Muro, Kristen Pierce, Mie Suzuki, Jennifer Vermette, Amit Oza

Gynecologic Oncology
2021
Subgroup of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Salmaan Khan, Adrish Sen, Catherine Kuzmicki, Ian MacNeil, Aaron Broege, Sarah Mutka, Kelly Brass, Ky McCracken, Laura Milligan, Kaija Kottke, Brian Sullivan, Lance G. Laing

2021 American Association of Cancer Research (AACR)
2020
Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Stefano Rossetti, Catherine Kuzmicki, Aaron Broege, Joanna Sabat, Salmaan Khan, Ian MacNeil, Brian Sullivan, Lance Laing

2020 American Association of Cancer Research (AACR)
2020
Test measuring signaling activity in live patient tumor cells identifies PI3KCA WT patients who may benefit from PIK3 inhibitors

Lance G Laing, Salmaan Khan, Ian A MacNeil, Catherine Kuzmicki, Benjamin Rich, Abhay Shukla, Kelly Brass, Brian Sullivan

2020 American Society of Clinical Oncology (ASCO)
2020
New HER2‐negative breast cancer subtype responsive to anti‐HER2 therapy identified. Journal of Cancer Research and Clinical Oncology 2020;146:605-619

Ian A. MacNeil, David J. Burns, Benjamin E. Rich, Sajjad M. Soltani, Samantha Kharbush, Nicole G. Osterhaus, Brian F. Sullivan, Douglas M. Hawkins, Jodie R. Pietruska, Lance G. Laing

Journal of Cancer Research and Clinical Oncology
2019
Sub-Group of PIK3CA WT breast cancer patients have hyperactive S1P and LPA signaling tumors responsive to PI3K inhibitors: functional signaling test identifies new patient group who may benefit from PI3K inhibitors

Lance G Laing, Salmaan Khan, Ian A MacNeil, Catherine Kuzmicki, Samantha Kharbush, Benjamin Rich, Abhay Shukla, Kelly Brass, Brian Sullivan

2019 San Antonio Breast Cancer Symposium (SABCS)
2018
Evaluation of pan-HER and c-MET inhibitors tested ex vivo in live primary HER2- breast cancer cells with hyperactive c-MET and ErbB family signaling

Laing, L., Burns, D., Khan, S., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Kharbush, S., Broege, AM., Brass, K., Mutka, S., Sullivan. B

2018 San Antonio Breast Cancer Symposium (SABCS)
2018
Evaluating contribution of hyperactive c-Met and ErbB signaling to tumor progression in mouse breast tumor xenografts: an in vivo study of c-Met and ErbB targeted therapies

Laing, L., Burns, D., Khan, S., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Kharbush, S., Brass, K., Sullivan. B

2018 San Antonio Breast Cancer Symposium (SABCS)
2018
Sub-group of HER2- breast cancer patients with hyperactive and co-involved c-Met and ErbB pathways identified: functional signal profiling test identifies patient group that may benefit from c-Met and pan-HER combination therapy

Laing, L., Burns, D., Khan, S., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Kharbush, S., Brass, K., Broege, AM., Mutka, S., Sullivan. B

2018 San Antonio Breast Cancer Symposium (SABCS)
2018
Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer

Lance G Laing, David J Burns, Salmaan Khan, Ian A MacNeil, Benjamin E Rich, Sajjad M. Soltani, Samantha Myhre, Brian F Sullivan

2018 American Society of Clinical Oncology (ASCO)
2018
A phase 2 study of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in HER2-negative breast cancer patients with abnormal HER2-driven signaling transduction (NCT03412643)

Eleftherios P. Mamounas, MD, MPH; Lance G Laing

2018 Miami Breast Cancer Conference
2017
Use of a functional signal profiling test to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit from anti-HER2 therapy

Lance G Laing, David J Burns, Ian A MacNeil, Benjamin E Rich, Sajjad M Soltani, Samantha Myhre, Brian F Sullivan

2017 San Antonio Breast Cancer Symposium (SABCS)
2017
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormal amplified HER2 signaling activity. Oncotarget. 2016 Oct 5;7(48) 78577-78590

Huang, Y., Burns, D., Rich, B., MacNeil, I., Dandapat, A., Soltani, S., Myhre, S., Sullivan, B., Furcht, L., Lange, C., Hurvitz, S., & Laing, L.

Oncotarget